Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.01 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | compounds already reach it: ataluren, mt-3724, citatuzumab bogatox +2 | 1.00 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 1 Parkinson's papers of 120 | 0.91 |
| pathways Reactome | 21 pathways; mostly other | 0.30 |
No case: the score is under the bar. Receipt 11486
Sealed predictions
- RPS26 in dopamine neurons, braak+0.00 (p 1.000) → +0.51 (p 0.160)receipt 11493
Swarm cases
receipt 11493: RPS26 in dopamine neurons, braak
- power
- full sample +0.15 (p 0.561, n 18), 95% CI -0.34 to +0.57. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.15 (p 0.544, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.22 (p 0.374, n 18). could be the mix.
- skeptic
- leave-one-out range +0.04 to +0.32, sign flips 0; without severely affected donors +0.15 (p 0.561, n 18). fragile.
- cell type
- strongest in astrocytes: +0.61 (p 0.0077, n 18) vs +0.15 in dopamine neurons. proposing astrocytes.
- axis
- no measure beats "tracks Braak Lewy-body stage" for RPS26 in dopamine neurons.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up RPS26 · astrocytes · braak: substantia nigra, an independent cohort (Parkinson's or LBD vs controls) +0.13 p 0.657 (needs p < 1.9e-4)
Receipts
loading the receipts